The effects of Tripterygium wilfordii Hook F on renal outcomes in type 2 diabetic kidney disease patients with severe proteinuria: a single-center cohort study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-6049 (Electronic) Linking ISSN: 0886022X NLM ISO Abbreviation: Ren Fail Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: New York, N.Y. : M. Dekker, c1987-
    • Subject Terms:
      Diabetic Nephropathies*/complications ; Diabetic Nephropathies*/drug therapy ; Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*; Humans ; Tripterygium ; Cohort Studies ; Retrospective Studies ; Proteinuria/drug therapy ; Proteinuria/etiology
    • Abstract:
      Aim: Tripterygium wilfordii Hook F (TwHF) has been shown to substantially reduce proteinuria in patients with diabetic kidney disease (DKD); however, the effect of TwHF on renal outcomes in DKD remains unknown. Accordingly, we aimed to establish the effects of TwHF on renal outcomes in patients with DKD.
      Methods: Overall, 124 patients with DKD, induced by type 2 diabetes mellitus, with 24-h proteinuria > 2 g, and an estimated glomerular filtration rate > 30 mL/min/1.73 m 2 were retrospectively investigated. The renal outcomes were defined as doubling serum creatinine levels or end-stage kidney disease. Kaplan-Meier curves and Cox regression analyses were performed to analyze prognostic factors for renal outcomes.
      Results: By the end of the follow-up, renal outcomes were observed in 23 and 11 patients in the non-TwHF and TwHF groups, respectively ( p  = 0.006). TwHF significantly reduced the risk of renal outcomes (adjusted hazard ratio [HR] 0.271, 95% confidence interval [CI] 0.111-0.660, p  = 0.004) in patients with chronic kidney disease (CKD) G3 (adjusted HR 0.274, 95%CI 0.081-0.932, p  = 0.039). Based on the Kaplan-Meier analysis, 1- and 3-year proportions of patients without renal outcomes were significantly lower in the non-TwHF group than those in the TwHF group (92.8% vs. 95.5% and 47.2% vs. 76.8%, respectively; p  = 0.0018).
      Conclusion: In DKD patients with severe proteinuria, TwHF could prevent DKD progression, especially in patients with CKD G3. A randomized clinical trial is needed to elucidate the benefits of TwHF on renal outcomes in patients with DKD.
    • References:
      Front Pharmacol. 2019 Nov 06;10:1250. (PMID: 31780926)
      Mol Ther Nucleic Acids. 2017 Dec 15;9:48-56. (PMID: 29246323)
      J Am Soc Nephrol. 2009 Aug;20(8):1813-21. (PMID: 19443635)
      BMC Med Res Methodol. 2013 Dec 07;13:152. (PMID: 24314264)
      Kidney Int. 2008 Sep;74(5):596-612. (PMID: 18509322)
      J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. (PMID: 31530577)
      Kidney Int. 2013 Dec;84(6):1108-18. (PMID: 23868014)
      N Engl J Med. 2020 Dec 03;383(23):2219-2229. (PMID: 33264825)
      Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. (PMID: 30635225)
      N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
      Clin Kidney J. 2022 Aug 24;16(1):52-60. (PMID: 36726436)
      Kidney Int. 2010 Jun;77(11):974-88. (PMID: 20375980)
      Am J Med Sci. 2015 Nov;350(5):345-51. (PMID: 26473333)
      Am J Kidney Dis. 2012 Nov;60(5):850-86. (PMID: 23067652)
      Diabetes Care. 2022 Jan 1;45(Suppl 1):S175-S184. (PMID: 34964873)
      N Engl J Med. 2020 Oct 8;383(15):1436-1446. (PMID: 32970396)
      Exp Ther Med. 2018 Apr;15(4):3874-3882. (PMID: 29581743)
      Am J Kidney Dis. 2020 Jan;75(1 Suppl 1):A6-A7. (PMID: 31704083)
      EClinicalMedicine. 2021 Dec 24;43:101240. (PMID: 35005582)
      Front Med (Lausanne). 2021 Sep 21;8:747922. (PMID: 34621768)
      Arthritis Res Ther. 2018 Apr 10;20(1):70. (PMID: 29636089)
      J Cell Physiol. 2018 Mar;233(3):2225-2237. (PMID: 28695984)
      Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. (PMID: 28522654)
      N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
      N Engl J Med. 2001 Sep 20;345(12):861-9. (PMID: 11565518)
      Ann Rheum Dis. 2015 Jun;74(6):1078-86. (PMID: 24733191)
      Exp Ther Med. 2013 Sep;6(3):649-656. (PMID: 24137241)
      Biol Pharm Bull. 2017 Nov 1;40(11):1833-1838. (PMID: 28867717)
      Kidney Int. 2011 Mar;79(5):555-62. (PMID: 21107446)
      J Clin Oncol. 2014 Aug 1;32(22):2380-5. (PMID: 24982461)
      J Transl Med. 2013 May 31;11:134. (PMID: 23725518)
      J Cardiol Cases. 2017 May 31;16(1):30-33. (PMID: 30279791)
      J Formos Med Assoc. 2020 Mar;119(3):685-692. (PMID: 31801679)
      Exp Clin Endocrinol Diabetes. 2016 Jun;124(6):389-98. (PMID: 27328403)
      Phytomedicine. 2022 Jul;101:154103. (PMID: 35468451)
      Nephrol Dial Transplant. 2010 Nov;25(11):3539-47. (PMID: 20483955)
      Diabetes Care. 2022 Dec 1;45(12):3075-3090. (PMID: 36189689)
      Phytother Res. 2019 Apr;33(4):1191-1198. (PMID: 30768745)
    • Contributed Indexing:
      Keywords: Tripterygium wilfordii Hook F; diabetic kidney disease; proteinuria; renal outcomes
    • Publication Date:
      Date Created: 20240105 Date Completed: 20240108 Latest Revision: 20240110
    • Publication Date:
      20240110
    • Accession Number:
      PMC10773657
    • Accession Number:
      10.1080/0886022X.2023.2295425
    • Accession Number:
      38178377